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1. Introduction 
1.1 Classifications 
Osteomyelitis represents the majority of severe bone infections. The localization of 
osteomyelitis originating in the bloodstream is most often the metaphysis of long bones 
[femur (36%), tibia (33%), and humerus (10%)] in children and vertebral bodies in adults 
(Lazzarini et al., 2004; Calhoun & Manring, 2005) (Figure 1).  
 
 
 
Fig. 1. Magnetic resonance tomography showing an osteolysis of the distal epiphysis of the 
left femur in an osteomyelitis case in a 40-year-old male patient. 
Contiguous-focus bone infections  from infected prosthetic devices are more frequently 
observed in adult males, who are more exposed to trauma (Jorge et al., 2009). Three 
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classifications are widely used in clinical practice. Waldvogel et al. (1970) described 
osteomyelitis according to duration, either acute or chronic. The disease is also classified 
according to the source of infection (i.e., hematogenous or contiguous focus). A third 
category defines osteomyelitis in terms of vascular insufficiency (Table 1).  
 
Duration Origin Sub-divisions 
Acute Hematogenous  
Contiguous focus No generalized vascular 
disease 
Generalized vascular disease 
Chronic Necrotic bone  
Table 1. Osteomyelitis staging system (adapted from Waldvogel et al., 1970) 
Nosocomial or traumatic transmissions are not considered in this classification system. 
Cunha (2002) suggested a simple classification based on acuteness (acute, subacute, or 
chronic) and microorganisms present for the elderly. The most recent classification system, 
based on anatomical, clinical, and radiologic features, was described by Cierny et al. (1985) 
(Table 2). Osteomyelitis is first defined by four stages, depending on the degree of extension: 
confined (medullary bone), superficial (cortical bone), localized (both), and diffuse. Second, 
the status of the patient (host) is considered, from A (healthy) to C (severely compromised). 
 
Stages Anatomical type Description 
1 Medullar Endosteal focus 
2 Superficial Limited to the surface of the bone 
3 Localized Full thickness of the cortical bone 
4 Diffused Entire cortical bone is involved 
Host Description Equivalent ASA status 
A Normal ASA 1 
B Bs: systemic compromise ASA 2 - 4 
Bl: local compromise 
Bsl: local and systemic 
compromise 
C Major comorbidities ASA 5 -6 
Table 2. Adult osteomyelitis staging system (adapted from Cierny et al., 1985) 
1.2 Microbiology  
In the case of acute osteomyelitis (AHO), the infection is caused by a hematogenous 
pathogen and is often located at a metaphysis (Table 3). Staphylococcus aureus is isolated in 
60-80% of cases (Gafur et al., 2008) with an increasing minimal inhibitory concentration 
(MIC) to methicillin, followed by other Gram-positive cocci (i.e., coagulase-negative 
staphylococci, Streptococcus spp.), Pseudomonas aeruginosa, and Escherichia coli (Lew & 
Waldvogel, 1997; Gutierrez, 2005; Saavedra-Lozano et al., 2008) (Table 4). Bacteria are 
isolated from blood cultures or tissue biopsy in only 45% in children. Incidence of 
osteomyelitis was found to reach one in 808 to more than 2,000 admissions (Georgens et al., 
2004; Weichert et al., 2008). Methicillin-resistant S. aureus (MRSA) represents approximately 
10% of the causative bacteria, except in the USA (40-50%) (Weichert et al., 2008). The 
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presence of Panton-Valentine leukocidin could explain the persistence and rapid local 
extension of AHO in humans (Crémieux et al., 2009; Labbé et al., 2010). 
 
< 1 year 1 to 16 years More than 16 years 
Group B streptococci 
Staphylococcus aureus 
Escherichia coli 
Staphylococcus aureus
Streptococcus pyogenes 
Haemophilus influenzae 
Staphylococcus epidermidis 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Serratia marcescens 
Escherichia coli 
Table 3. Organisms commonly isolated in osteomyelitis based on patient age (adapted from 
Dirschl et al., 1993) 
 
Bacteria Circumstances 
Staphylococcus aureus All types of osteomyelitis 
Coagulase-negative staphylococci or 
Propionibacterium species 
Foreign-body–associated infection 
Enterobacteriaceae sp or Pseudomonas 
aeruginosa 
Nosocomial infections 
Streptococci or anaerobic bacteria Wounds infected by saliva, diabetic foot 
lesions, decubitus ulcers 
Salmonella species or Streptococcus 
pneumoniae 
Sickle cell disease 
Bartonella henselae, Aspergillus sp, 
Mycobacterium avium-intracellulare or 
Candida albicans 
Immunocompromised patients 
Pasteurella multocida or Eikenella corrodens Bites 
Table 4. Main bacteria isolated in bacterial osteomyelitis (adapted from Lew et al., 1997) 
1.3 Diagnosis and treatment 
The clinical picture of AHO is often classic: it is commonly a child from 6 to 12 years of age 
who suddenly presents with a disability absolved from the affected limb and associated 
with a 39-40°C fever. After clinical investigation, the pain is extremely intense, and the 
preferential location is the lower extremity of the thighbone or the superior extremity of the 
shin. Emergency treatment must be initiated, associated with fixed immobilization in plaster 
and intravenous antibiotic therapy. If the treatment is administrated early, cure is most often 
achieved within 3 weeks. If a delay in diagnosis is made or the treatment is inadequate, 
chronic osteomyelitis associated with a 38°C fever can develop and the affected limb aches, 
is red and warm, and sometimes abscesses. Radiography shows osteolysis at the 
metaphysis, with thickening or detachment of the periostium with ossification and 
appearance of a sequestrum. The treatment of these forms, which can become subacute or 
chronic, is complex and is often associated with 6 months to 1 year of medical treatment and 
repeated surgical procedures to remove intra-osseous or under-periostium abscesses and 
sequestra. The after-effects are important: osseous fragility with risk of fracture and 
disorders of healing and growth in length or with deviation. The osteitis is usually subacute 
with S. aureus and more or less painful. When osteitis affects a lower limb, patients have a 
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limp, and clinical examination shows amyotrophy regarding the skeletal area of interest. 
The biology shows all the signs of infection (leucocytosis, erythrocyte sedimentation rate, C-
reactive protein); radiology reveals evidence of uni- or polycyclic osteolysis that is finely 
encircled by dense bone (Brodie’s abscess). Surgical treatment is necessary, and osseous 
trepanning is performed to decompress this internal infection, administering antibiotics 
intravenously first and then orally. The duration of treatment is at least 3 weeks. If 
everything does not quickly normalize, oral antibiotics are necessary for several months. 
Osteomyelitis is an infective process that may also require numerous surgical interventions 
and leads to bone sclerosis and deformity, and even to a loss of limb.  
2. Animal experimental models  
Clinical trials for antibiotic treatment of osteomyelitis are rare and difficult to perform for 
many reasons. First, the anatomical localization of the lesions varies. Moreover, the 
treatment of patients suffering from severe bacterial infection with new drugs raises 
complicated ethical concerns that must be addressed. In vitro alternatives to replace 
animal tests, specifically to study osteomyelitis due to MRSA, are unrealistic and do not 
allow for surgical procedures. For these reasons, animal studies are the most appropriate 
and feasible way to assess the impact of antibiotic therapy on the outcome of 
osteomyelitis. Several different models exist and were developed to study hematogenous 
(or post-traumatic) osteomyelitis or osteomyelitis related to orthopedic implants and 
prosthetic joint infections. The features and history of these osteomyelitis models have 
been summarized by several authors (Mader, 1985; Norden, 1988; Rissing, 1990; Patel et 
al. 2009). Further, osteomyelitis studies have been conducted using various species, 
including rats (Power et al. 1990), rabbits (Andriole et al., 1973; Norden 1988), dogs 
(Deysine et al., 1976; Fitzgerald, 1983), and guinea pigs (Passl et al., 1984)., each with 
advantages and limitations.  
2.1 Limitations and failures 
The osteomyelitis experimental model is demanding but critical for testing new antibiotics 
because eradication of bacteria from bone represents a very difficult challenge (Yin et al., 
2005). In experimental studies, viable bacteria can be retrieved from the bone despite 
prolonged antibiotic treatment (i.e., up to 4 weeks). The development and maturation of 
bacterial biofilms could explain the failure of antibiotic treatments and subsequent relapses 
(Brady et al. 2008). However, current animal models of osteomyelitis have a number of 
limitations, including low success rates for the induction of osteomyelitis, the elimination of 
causative bacteria by the host immune system, and the need for administration of sclerosing 
agents (SAs) in most cases (Patel et al., 2009). These SAs, as morrhuate sodium or its 
derivative arachidonic acid, are thought to induce varying degrees of aseptic bone necrosis, 
providing ideal conditions for bacterial proliferation and likely facilitating bone infection by 
occluding the microvasculature. In most animal models of osteomyelitis, SAs are usually 
injected prior to bacterial injection (Yoshii et al., 2001; Fukushima et al., 2005). 
2.2 The acute rabbit model 
In the acute model developed by Gaudin et al. (2011), devascularized bone made from a 
surgically induced bone defect provided a site in which to establish a productive infection. 
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Femoral trepanation using a biopsy needle was followed by injection of 1 mL of 109 colony-
forming units (CFU)/mL S. aureus suspension directly into the knee cavity. Using this 
protocol, bacterial densities approached 9-log10 CFU/g infected tissue 3 days post-infection 
that persisted at least 14 days without treatment. Unlike chronic models of osteomyelitis, no 
spontaneous recovery of the bacterial infection was observed. Moreover, the rabbit long 
bone model is appropriate for the study of osteomyelitis because rabbits are more prone to 
infection than other animals, such as rats. The size of New Zealand white rabbits makes it 
possible to more closely mimic human surgical procedures such as bone debridement and 
computer-controlled pharmacokinetic .  
 
 
Fig. 2. The acute experimental osteomyelitis rabbit model (Gaudin et al., 2011) 
3. Calcium phosphate as a matrix of antibiotic release   
The term “biomaterial” has recently been defined as “a substance that has been engineered 
to take a form that, alone or as part of a complex system, is used to direct…the course of any 
therapeutic or diagnostic procedure” (Williams, 2009). Implantable biomaterials are inert or 
can promote biological activities, such as bone regeneration, or minimize undesirable 
activities, such as infection or blood clotting (Williams, 2008, 2009). 
In the osseous and dental fields, biomaterials are often necessary to fill or treat different 
pathological situations, such as bone trauma, infections, irradiations, or various diseases 
such as osteoporosis and tumor resection (Campoccia et al., 2010). As alternatives to bone 
grafts, different biomaterials have been developed. 
3.1 Biomaterials 
Inorganic materials are frequently used as bone matrixes and are divided into three 
chemical families that represent current alternatives to biological bone grafts: calcium 
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phosphate (CaP), calcium sulphate, and calcium carbonate. These materials can be shaped 
into different forms such as powders, granules, ceramics, cements, and coating, depending 
on the site, and the size and shape of the bone defect. Granules are more convenient than 
blocks, allowing the replacement of a large bone volume. As blocks are difficult to fit into 
cavities, vacant areas are often observed between blocks and bone. Vertebrate bone tissue is 
primarily composed of CaP, which explains why CaP materials are excellent candidates for 
bone reconstruction (Rush, 2005; Vallet-Regi, 2006: LeGeros, 1991). CaP materials are also 
interesting because of their cell resorption and osteoconductive properties. Calcium 
sulphate and calcium carbonate are less frequently used because they promote poor osseous 
formation because of their higher solubilities.  
Based on composition, currently used synthetic CaP matrixes are classified as 
hydroxyapatite [HA: Ca10(PO4)6(OH)2], alpha- or beta-tricalcium phosphate [ǂ or ǃ-TCP : 
Ca3(PO4)2], mixtures of these compounds, biphasic CaP (BCP), or unsintered apatites called 
calcium-deficient apatite (CDA). 
HA and ß-TCP ceramics can be prepared by grinding CaO and P2O5 powders with Ca/P 
equal to 1.67 and 1.5, respectively. These mixtures must be sintered at more than 1100°C. 
These CaP biomaterials differ in their extent of dissolution (Chow, 2009):  
 ǂ-TCP >> CDA> ǃ-TCP >> HA  
CDAs can be prepared either by aqueous precipitation from calcium and phosphate salts or 
alkaline hydrolysis of acidic CaP (Jarcho, 1981; Gauthier et al., 1998; Venesmaa et al., 2001; 
Nehme et al., 2003). For BCPs, the dissolution rate depends on the HA/TCP ratio: the higher 
the ratio, the higher the dissolution (LeGeros, 1991; Daculsi et al., 1997). HA, TCP, BCPs, and 
CDA are frequently described in the literature as excellent candidates for bone substitution 
because of their similarity to bone structures (Figures 3 and 4).  
 
 
Fig. 3. Scanning electron micrograph picture of BCP at a magnification of 5000. 
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Fig. 4. Scanning electron microscopy picture of CDA at a magnification of x10 000. 
These materials have all the necessary properties required for a graft: biocompatibility, 
bioactivity, biofunctionality, and osteoconductivity. Because of CDA's better solubility than 
BCP, bone colonization with CDA will be quicker and more significant and will thus 
provide a better reconstitution of the bone. 
Others matrix properties are also very important. Macroporosity, which corresponds to 
pores larger than 100 µm, defines its capacity to be colonized by cells. Different agents can 
be associated with the matrix during the preparation process (naphthalene or sucrose 
particles and granules) and then calcinated or sublimated at high temperature (Lecomte et 
al., 2008; Le Ray et al.; 2010). Microporosity, corresponding to pores smaller than 10 µm, 
defines the matrix capacity to be impregnated by biological fluids. These micropores depend 
on the sintering process, and the microporosity depends mainly on the material composition 
and the used thermal cycle. Solubility and biological properties of these CaP materials 
depend on crystal size, ionic impurities, specific surface area, and porosity. The control of 
the macro- and micropore size and distribution of CaP bone substitutes represent the most 
important parameters to promote or induce bone formation. All these parameters have a 
specific influence on the final mechanical properties of the bioceramics (Bouler et al., 1996). 
CaP biomaterials possess three fundamental properties that govern potential bone 
substitution:  
- Biocompatibility: CaP ceramics are perfectly tolerated by the host organism, as 
described by numerous studies (Deligianni et al., 2001; Ooms et al., 2003; Julien et al., 
2007; Williams, 2008), 
- Bioactivity: After implantation, the biological fluids interact with the CaP ceramics and 
initiate the dissolution of the material. Depending on the chemical composition of the 
CaP ceramics, a precipitation of a layer of biological apatite can be obtained on their 
surfaces. The continuity thus obtained between the host bone tissue and the biomaterial 
promotes cellular colonization and the formation of bone tissue. The cellular resorption 
and degradation of the bone substitute results from the concomitant action of 
osteoclasts and macrophages, respectively (Anderson & Miller, 1984; Minkin & 
Marinho, 1999; Detsch et al., 2008). The resorption rate of the material and the de novo 
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bone tissue rate ideally must be similar to ensure stability of the interface (Zerbo et al., 
2005). The biological, chemical, and mechanical properties at the bone/material 
interface are therefore essential to ensure good osteointegration of the implant 
(Ducheyne & Cuckler, 1992). 
- Biofunctionality (Daculsi et al., 1999; Parikh, 2002; LeGeros, 2002): The material 
mechanical properties of CaP ceramics are limited by low initial mechanical properties 
compared to host bone mechanical properties. However if osteoconduction and 
resorption are favored (e.g., by a convenient porous structure), the fragility of the CaP 
ceramic implant is going to decrease, and an optimal final biofunctionality will be 
achieved with the total resorption/substitution process. Therefore, intrinsic material 
parameters [e.g., rate of porosity and solubility (Ca/P ratio)] and extrinsic parameters 
(e.g., primary stability, instrumentation) must be adapted to promote both complete 
implant resorption and tissue regeneration. Then, the three functions (mechanic, 
metabolic, and hematopoietic) of bone can be fully restored.  
3.2 Biomaterials as drug delivery systems 
The “fill-in” properties are interesting but rapidly it became necessary to not only fill in 
osseous or dental defects (Navarro et al., 2008) but to treat locally different pathologies. 
Thus, several combinations of biomaterial matrices and therapeutic agents were prepared. 
Such biomaterials are called drug delivery systems (DDS). First, polymethylmethacrylate 
cements were tried as innovative drug delivery systems, but these materials were 
progressively replaced by resorbable materials whose major advantage is to be left in situ in 
the bone defect and do not require surgical removal. These materials are numerous, ranging 
from inorganic to organic and from natural to semi-synthetic or synthetic. 
Therapeutic agent-CaP biomaterial combinations prepared to produce an in situ DDS with a 
sustained release profile were numerous; a large panel of therapeutic agents loaded onto 
biomaterials was used, including growth factors (Verron et al. 2010) such as bone 
morphogenetic proteins (Ripamonti et al., 1992; Deckers et al., 2002), human growth 
hormone (Goodwin et al., 1995; Downes et al., 1995; Guicheux et al., 1998), transforming 
growth factor-beta (Kim et al., 2005), insulin-like growth factor (Matsuda et al., 1992); 
antiosteoporotics (Denissen et al., 1994, 1997; Golomb et al.,1992); anticancer drugs (Otsuka 
et al., 1995; Itokazu et al., 1998); insulin (Otsuka et al., 1994); steroid hormones (Bajpai & 
Benghuzzi, 1988); analgesic drugs (morphine and lidocaine (Gautier et al., 2010), and 
antibiotics (Penner et al., 1996; Suzuki et al., 1998). 
Concerning antibiotics, the incorporation of antibacterial therapeutic agents in biomaterials 
dates back to the 1950s with the association of dental cements and resins with antibiotic 
drugs. The idea was to release locally therapeutic agent at the infection site. As cements and 
resins are not bioresorbable, other biomaterials that are resorbable and soluble were 
developed. Therapeutic agent release must be controlled to ensure adequate tissue 
concentrations several times higher than the MIC and maintained sufficiently to entirely 
cover the difficult post-surgery period, avoiding the systemic administration of intravenous 
or oral antibiotics and their subsequent side effects. Among the antibiotics (Sudo et al., 
2008), gentamicin sulphate (Specht & Kühn, 1998) and crobefat (Joschek et al., 1998), 
cephalexin (Yu et al., 1992), tobramycin (Nijhof et al., 1997; Anaja et al., 2008), arbekacin 
(Itokazu et al., 1997), ciprofloxacin ((Wu et al., 1997), isepamicin sulphate (Itokazu et al., 
1998; Kawanabe et al., 1998), gentamicin (Randelli et al., 2010), and vancomycin (Hamanishi 
et al., 1996) are commonly used for these associations. Recently, a new DDS using linezolid 
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was developed (Gautier et al., 2010). Tetracyclines cannot be used with CaPs because their 
fixation to the matrix is irreversible (Misra, 1991). Tetracycline is moreover used as a tracer 
for forehead mineralization in histology studies but is not used for the treatment of children. 
3.3 Associating therapeutic agents with biomaterials 
Various techniques associating a therapeutic agent with a CaP biomaterial have been 
reported in the literature: powder-powder mixing (Yu et al., 1992; Dacquet et al., 1992; 
Hamanishi et al., 1996; Trécant et al., 1997); soaking of beads (Thomazeau & Langlais, 1996; 
Brouard et al., 1997), granules (Joschek et al., 1998), or blocks (Prat-Poiret et al., 1996) in a 
therapeutic agent solution; packing the therapeutic agent in a central, cylindrical cavity in 
porous blocks (Shinto et al., 1992) or in the central cavity of TCP capsules to maintain high-
level, long-term release of the therapeutic agent (Wu et al., 1997); adsorption of the 
therapeutic agent in solution on the biomaterial (Guicheux et al., 1997; Trécant et al., 1997; 
Gautier et al., 1998); centrifugation (Itokazu et al., 1995; Nijhof et al., 1997; Itokazu et al., 
1994a, 1998d, 1998e, 1998f); or immersion of a biomaterial block in a therapeutic agent 
solution followed by vacuum (Itokazu et al., 1998f; Kawanabe et al., 1998). Adsorption and 
soaking both allow the therapeutic agent to be incorporated at the surface of the biomaterial, 
whereas centrifugation and vacuum enable the therapeutic agent to enter the pores of the 
biomaterial. These different processes of therapeutic agent–matrix association are chosen to 
either facilitate contacts between the biomaterial and the therapeutic agent or achieve 
compaction. At the same time, our laboratory has dismissed the use of wet granulation and 
developed two compaction techniques: dynamic compaction and isostatic compression for 
the successful preparation of sustained-release forms. 
The technique of wet granulation, a densification technique widely used in the 
pharmaceutical industry for the manufacture of granules and pellets, is commonly used for 
the association of CaP (CDA or BCP) with the therapeutic agent, making it possible to 
acquire a homogeneous distribution of the constituents of the granules and create close links 
between CDA and the therapeutic agent (Ormos, 1994). In addition, the acquired granules 
have a spherical form that is suitable for filling bone defects. This technique has already 
been used for bone substitute formulations with vancomycin and linezolid (Gautier H et al., 
2000). A particle size analysis by laser light diffraction can be performed on acquired 
granules after sieving of the fraction (40- to 80-µm fraction, 80- to 200-µm fraction, 200- to 
500-µm fraction, depending on the defect size). The results show that a large majority of the 
granules belong to the required fraction. If necessary, and to select more precisely the 
fraction desired, aspiration with an air jet sieving machine can be performed. 
Dynamic compaction is a powder compaction technique developed in 1995 to consolidate 
CaP powders (Trécant et al., 1997). During this process, particle surfaces are highly 
deformed, producing interparticulate bonding in a one-step procedure. This process occurs 
during the passage of a shock wave through the powder. As this technique requires no 
external heat and allows the compaction to be formed without a sintering step, a heat-
sensitive therapeutic agent can be associated with a CaP powder without denaturing the 
active element. The agent and powder can be melted and associated before compaction, and 
the pressure can vary between 0.5 and 2 MPa. Different studies showed the advantage of 
dynamic compaction to obtain compact CaP biomaterials (Trécant et al., 1995) and to 
associate therapeutic agents with those materials (Guicheux et al., 1997; Trécant et al., 1997). 
These studies investigated the association of growth factors (e.g., human growth hormone) 
and antibiotics, such as vancomycin and polymyxin B, with the CaP matrix (CDA and BCP). 
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The physicochemical characterization of CaP granules by X-ray diffraction, infrared 
spectroscopy, and nuclear magnetic resonance showed that the structures of BCP and 
vancomycin were unchanged by dynamic compaction at 1.9 MPa. This finding was 
concordant with another study (Trécant et al., 1995), showing that the structures of powders 
such as hydroxyapatite, -CaP, BCP, and octacalcium phosphate were conserved after a 2-
MPa dynamic compaction. Scanning electron microscopy showed that granule porosity 
depends on the manufacturing process, ranging between 37.7 ± 6.8 and 9.9 ± 4.7%. Granule 
porosity with dynamic compaction was 3-to 4-fold lower than with wet granulation. In fact, 
the wet granulation process is performed during a single step in which densification occurs, 
whereas granule preparation is done in two steps with the dynamic compaction process: 
densification by powder volume reduction (which gives a compact with lower density) 
followed by crushing. This volume reduction is correlated with the pressure applied 
(porosity is reduced when compaction pressure is high). As bone ingrowth correlates with 
material porosity (Lu et al., 1999), the choice of preparation process allows various granules 
to be obtained. 
Polymyxin B, a polypeptidic antibiotic that undergoes thermodamage above 60°C, was also 
studied and associated with CaP by dynamic compaction (Kimakhe et al., 1999). The 
biological activity of polymyxin B-loaded CaP was determined by the effect of the antibiotic 
and monocyte/macrophage degradation on compact surfaces. The biological activities (i.e., 
antibacterial activity and inhibited lipopolysaccharide effects on monocyte/macrophage 
CaP degradation) of polymyxin B released from compacted calcium-deficient apatite were 
unaltered. Thus, dynamic compaction allows polymyxin B to be used with CaP ceramics 
without any loss in integrity or biological effects. 
Isostatic compression is a technique based on the transmission of an isostatic omni-
directionnal hydraulic pressure to powder, thus making the materials denser within a few 
minutes at room temperature. This cold technique allows the association of drugs without 
any degradation and allows the direct preparation of a correctly and directly molded 
implant. Compression pressure is applied uniformly and from all directions to consolidate 
the material (Gautier et al., 2000a, 2000b). 
Physicochemical characterization of BCP granules by X-ray diffraction, infrared 
spectroscopy, and nuclear magnetic resonance showed that BCP, linezolid, and vancomycin 
structures remained the same. After association, release profiles must be determined to 
characterize the biomaterials. To establish the granule release profiles of the therapeutic 
agents, different tests can be used: culture chamber dissolution tests (Guicheux et al., 1997) 
or paddle apparatus dissolution tests (European Pharmacopoeia 7.1). Proportions of 
therapeutic agents released daily from a CaP matrix must be measured by an UV–visible 
spectrophotometric or high-pressure liquid chromatography (HPLC) assay. 
Generally, using the culture chamber dissolution test, independent of the therapeutic agent 
(e.g., vancomycin or linezolid), after a waiting time of approximately 6 hours, the kinetics 
were observed to be order 0 up to a complete release in 3 to 26 days, depending on the 
amount of therapeutic agent loaded, its solubility, and the process of association. The 
waiting time of 6 hours, noticed before the beginning of the release of the antibiotic, 
corresponds to the time of the anchoring of grains, necessary at the beginning of the 
dissolution of the antibiotic in the medium. 
For example, in wet granulation, the process allows a faster delivery, releasing the 
associated vancomycin in a maximum of 3 days. Dynamic compaction increases the period 
of vancomycin release to 4 to 6 days. Granules obtained by this process form a matrix that 
releases the therapeutic agent slowly, depending on the binding force (not yet determined) 
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of vancomycin to CaP. The pressure of dynamic compaction has no significant influence on 
release time, and there was no significant difference in the vancomycin adsorbed on 
granules prepared by dynamic compaction or compacted with BCP granules. In the first 
case, the water of the dissolution medium penetrates into the pores to release the 
therapeutic agent; in the second case, a vancomycin dissolution-diffusion process operates 
from the periphery toward the center of the granule.  
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Fig. 5. Vancomycin release profiles from BCP granules prepared by different techniques.  
Another study compared wet granulation and isostatic compression (Gautier et al., 2000b). 
Release was faster for granules prepared by wet granulation than for those prepared by 
isostatic compression. Moreover, vancomycin release time was prolonged as compression 
increased: an increase in isostatic compression from 100 to 200 MPa allowed a doubling of 
75% vancomycin release. The use of isostatic compression allowed a 3- to 5-fold increase in 
the period of vancomycin release compared to granules prepared by wet granulation. These 
differences in the rate of vancomycin release may have been due to the nature of BCP-
vancomycin binding strength. Vancomycin is always released faster when associated by 
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adsorption at the surface of the granule compared to direct incorporation into the granule 
mass, regardless of the manufacturing process used. Release is also faster for wet 
granulation than for isostatic compression. Moreover, therapeutic agent release slows as 
isostatic pressure increases. Figure 5 shows different vancomycin release profiles from 200- 
to 500-µm BCP granules prepared by isostatic compression, wet granulation, and dynamic 
compaction. 
Scanning electron micrographs show that granules prepared by wet granulation have a 
greater number of macropores and those prepared by isostatic compression possess a 
greater number of micropores (Figure 6). Image analysis also indicates that porosity is 
greater for granules prepared by isostatic compression. Pores of granules prepared by wet 
granulation appear to be more accessible to the release medium, thereby increasing the rate 
of vancomycin release. Moreover, the porosity percentage for granules prepared by isostatic 
compression is greater as isostatic pressure increases. 
 
 
 
6a: porosity = 33.93 ± 4.29 % 
 
 
 
6c: porosity = 47.92 ± 5.94 % 
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6b 
porosity = 63.4 ± 14.30 % 
 
6d 
porosity = 42.71 ± 7.48 % 
Fig. 6. Scanning electron micrographs of BCP granules. BCP granules (200- to 500-µm) were 
prepared by wet granulation (a) and isostatic compression at 100 MPa (b), 140 MPa (c), and 
200 MPa (d). Porosity percentages are expressed as the mean ± SD (Gautier et al., 2000b) 
Another study was performed on CDA granules containing linezolid associated by a wet 
granulation process (Gautier H, Biomaterials 2010). Figure 5 shows images of CDA 
containing 10% linezolid (a) and 50% linezolid (b) acquired by scanning electronic 
microscopy. A comparison of the slope of the linear regression was made. For 10% linezolid-
loaded granules, the slope (p) was equal to 17.068 with correlation coefficient r² = 0.994; for 
50% linezolid-loaded granules, p = 5.11 and r² = 0.9969. For granules containing 10% 
linezolid, the release was rather quick (3.3 times more important for 10%-loaded granules 
than for 50%-loaded granules). After a waiting time of approximately 6 hours, the kinetics 
observed were order 0 up to a complete release in 9 days. The results of the release kinetics 
for CDA loaded with 10% linezolid were similar to those observed for vancomycin 
integrated into BCP, although with a slightly longer release time. For the release kinetics of 
CDA containing 50% linezolid, the release kinetics were similar, with a waiting time from 
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approximately 6 hours, and kinetics of order 0. The release was complete after 26 days, 
which is three times greater than for grains loaded with 10% linezolid.  
 
 
   7a)     7b) 
Fig. 7. CDA containing 10% linezolid (a) and 50% linezolid (b) acquired by scanning 
electronic microscopy at a magnification of ×250 (Gautier et al., 2010a) 
Another laboratory (Kundu et al., 2010) developed HA-based porous scaffolds loaded with 
ceftriaxone-sulbactam (i.e., a drug combination consisting of an irreversible ǃ-lactamase 
inhibitor and a ǃ-lactam antibiotic) and presented that results of in vitro and in vivo drug 
elution after 41 days showed release rates higher than minimum inhibitory concentration of 
ceftriaxone-sulbactam against S. aureus in a chronic osteomyelitis model. 
Additionally, there is no correlation between these in vitro release results, the release test 
used, and the in vivo therapeutic agent released. It appears to be important to choose the 
fabrication process in terms of the needed release time: a flash release of just a few days to 
avoid infections after surgical intervention or long-term release at high concentrations after 
bone infection.  
It is important to demonstrate the effectiveness of the antibiotic released from the granules. 
This can be performed by nuclear magnetic resonance-mediated structural identification as 
well as by antibacterial assay. The analysis by 1H- nuclear magnetic resonance (1H-NMR) 
must be performed on samples of CaP granules to verify that the association process does 
not modify the CaP structure. 1H-NMR analysis must also be performed on samples of CaP 
granules loaded with therapeutic agent to identify the structure of the therapeutic agent 
molecule in the different samples regardless of the percentage of therapeutic agent 
associated. Analysis performed on BCP and CDA showed that wet granulation, isostatic 
compression, and dynamic compaction processes did not affect the structure of the CaP 
matrices. Analysis performed either on vancomycin or linezolid showed that the 
incorporation of pharmacological agents into CDA and BCP by wet granulation and 
isostatic compression did not affect the structure of the antibiotic. The chemical structure of 
the vancomycin and linezolid remained identical in granules even during release. In fact, no 
significant spectral differences were noticed during the NMR analyses of the therapeutic 
agent molecule released and extracted from the release profiles from 24 hours to 7 days. 
The bacteriological test consists of measuring the amount of therapeutic agent still active in 
samples after its release. Bacterial strains must be shown to be sensitive to the therapeutic 
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agent, and the matrices (i.e., CDA and BCP) do not inhibit the bacterial growth of the 
bacterial strain. The ratio of the therapeutic agent (i.e., vancomycin or linezolid) quantities 
calculated by bacteriological and assay measurements, derived from release kinetics of the 
granules after 24 hours, 5 days, or 7 days of release are determined and correlated to the 
NMR analyses, showing that the chemical structures of the released vancomycin and 
linezolid were maintained. It can be concluded that the manufacture of granules by wet 
granulation and isostatic compression, as well as the tests of release, changes neither the 
structure nor the activity of the vancomycin or linezolid, and thus, the antibiotics might be 
able to treat bone infection. However, a comparison of the amounts of activity detected by 
spectrophotometry and microbiological assay shows that only 28% of the vancomycin 
released from biomaterials prepared by dynamic compaction was active. This compaction 
technique is known to cause large but brief local temperature increases in compact 
materials, which are not quantifiable but high enough to induce grain joint formation. This 
process could denature vancomycin activity, which remains stable for 6 h at 80°C. As 
dynamic compaction reduces the microbiological activity of vancomycin, wet granulation 
and isostatic compression processes are preferred. 
As a result, according to the nature of the implant and the release profiles of the different 
therapeutic agents, surgeons will be able to choose the most appropriate biomaterial (blocks, 
grains, or powders) for their patients. 
4. CDA as a vancomycin delivery system: results 
4.1 Rationale 
In this study, we evaluated whether CDA could be used as a local DDS for vancomycin. The 
antibacterial activities of CDA loaded with 10% vancomycin over 14 days, in the presence or 
absence of a standard systemic treatment of vancomycin, were assessed using an in vivo 
model of acute MRSA osteomyelitis (Amador et al., 2010; Gaudin et al., 2011).  
4.2 Materials and methods 
4.2.1 Animals 
Female New Zealand rabbits (2.0 to 2.5 kg) used in this study were individually caged and 
had free access to water and food. Experiments were performed according to the Committee 
of Animal Ethics of the University of Nantes, France. Animals soon to be moribund (i.e., 
having difficulty accessing water and food associated with 10% weight loss per day for 2 
days) were euthanatized by lethal injection of thiopental under general anesthesia. A 
fentanyl patch (Durogesic, Janssen-Cilag Lab.) was used for pain management. Due to the 
delay of action (approximately 12 hours), the patch was placed on the animals the night 
before beginning the experiment (induction) and changed every 72 hours. 
4.2.2 Bacterial strain 
The MRSA strain used in this study was isolated from a blood culture and exhibited 
heterogeneous, low-level methicillin resistance (methicillin MIC=16 µg/mL). Molecular 
characterization showed this strain has a cassette chromosome SCCmec type IVa and agr-1 
and was Panton-Valentine leukocidin toxin- and toxic shock syndrome toxin-negative. 
The MRSA vancomycin MIC was 2 µg/mL. Inocula (CFU per mL) were adjusted to 109 
CFU/mL.  
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4.2.3 Bacterial counts 
Bacterial counts were determined after 48 hours of incubation at 37°C on tryptic soy agar 
plates. To evaluate whether vancomycin treatment induced the selection of in vivo-resistant 
variants, undiluted sample homogenates were spread on agar plates containing 8 µg/mL 
vancomycin, 4-fold greater than the MIC. 
4.2.4 DDS synthesis 
The most efficient concentrations of antibiotics were previously determined by in vitro and 
in vivo analyses (Amador et al., 2010). Granules containing 10% vancomycin were prepared 
by wet granulation. The size of the granules was determined to be 200-500 µm, compatible 
with common handling human practice. 
4.2.5 Vancomycin tissue measurements 
Dosages of vancomycin in joint fluid, bone marrow, and spongy bone were realized at 
=214 nm by HPLC (ThermoFisher Spectra System SCM1000/P1000XR, with automatic 
syringe AS3000 and UV6000LP detectors and FL3000). The column was a C18RP (Hypersil 
GOLD, 150-mm length, 5 µm × 4.6 mm, ThermoFisher). The isocratic mobile phase was 12% 
acetonitrile in an ammonium acetate buffer adjusted to pH 6 by phosphoric acid. 
Experiments with every range and dosage were performed in triplicate. 
4.2.6 Experimental design 
Animals were randomly assigned to six groups: (1) vancomycin group V(IV) [vancomycin 
constant intravenous infusion to reach a 20× MIC serum steady-state concentration (CIV)] 
for 4 days; (2) V(CDA10%) (CDA loaded with 100 μg/mg vancomycin) for 4 days or (3) for 14 
days; (4) V(IV) for 4 days + V(CDA10%) (CDA loaded with 100 μg/mg) for 4 days (5) or 14 days 
(6) for vancomycin tissue measurement.  
We used a percutaneous, transarticular route to perform femoral trepanation using a 
Jamshidi bone marrow biopsy needle under general anesthesia. The Jamshidi needle was 
inserted between the two femoral condyles and through the epiphysis, physis, and 
metaphysis to reach the medullar canal. After the needle was removed, the skin incision was 
closed. Subsequently a 1-mL suspension containing 109 CFU MRSA was injected 
parapatellarly into the knee cavity. At day 3, osteomyelitis was induced, causing unbridling, 
and the infected site was washed as recommended in human practice. Samples of joint fluid, 
bone marrow, and spongy bone were removed for bacterial counts. At day 7 or 17 post-
inoculation, animals were euthanized to measure the bacterial load in the joint fluid, bone 
marrow, and bone. Results were expressed as the bacterial counts (log10/g of tissue) at day 3 
(reference level) and either day 7 or 17. The lower limit of detection for this method was 1 
CFU/50 µl undiluted tissue homogenate. Infusions of antibiotics began at day 3 and 
continued for only 4 days due to ethical reasons.  
4.2.7 Statistical analysis 
Statistical analyses were performed using Graphpad Prism® 4 for Windows (Graphpad 
Software, San Diego, CA, USA). Results were expressed as the means ± standard deviation. 
Regimens were compared using one-way analysis of variance. This analysis was performed 
using a post-hoc Student-Newman-Keuls test. Time-dependant efficacy was tested by a non-
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parametric t test associated with a Wilcoxon post-test. P less than 0.05 was considered 
statistically significant. 
4.3 Results and discussion 
4.3.1 Vancomycin tissue measurements 
Wysocki et al. (2001) demonstrate that CIV patients (targeted plateau drug serum 
concentrations of 20 to 25 mg/L) reached the targeted concentrations faster, and fewer 
samples were required for treatment monitoring than with intermittent infusion patients 
(IIV). For comparable efficacy and tolerance, CIV may be a cost-effective alternative to IIV. 
Samples of plasma, spongy bone, and bone marrow were analyzed for vancomycin by 
HPLC in healthy and infected femurs. Vancomycin concentrations were 7.50  2.48 µg/g in 
bone marrow and 6.11  3.18 µg/g in spongy bone in healthy tissues, associated with a 
vancomycin plasma level of 19.09  3.79 µg/mL. For infected bone tissues, vancomycin 
concentrations were 6.70  2.23 µg/g, 12.63  5.16, and 22.63  8.53 for bone marrow, spongy 
bone, and plasma, respectively, related to the vancomycin MCIs of the causative MRSA (2 
µg/mL). The constant infusion of vancomycin exhibits more than three times the MICs of 
the studied strain in any compartment. 
For the CDA loaded with 10% vancomycin group (without a systemic approach), samples 
were taken at the maximum local delivering time (24 hours): plasma for vancomycin dosage 
and bone marrow and spongy bone, near the CDA implants, to assess local tissue delivery. 
Vancomycin plasma levels were 3.36  0.81 µg/mL, corresponding to a very weak elevation. 
Local bone tissue concentrations were more than 100 times and 150 times the vancomycin 
MICs for the MRSA strain for bone marrow and spongy bone, respectively. Surprisingly, the 
introduction of CDA loaded with 10% vancomycin did not significantly increase the plasma 
concentration obtained at steady-state by continuous infusion of vancomycin, reducing the 
risk of general toxicity. In contrast, the contribution of local antibiotic-loaded material 
appeared to be considerable. 
4.3.2 Bacterial counts 
No vancomycin-resistant mutants were detected after either 4 or 14 days of treatment in any 
group and in any compartment. 
Data from the in vivo experiments are summarized in Table 5. Because infusion caused 
major venous time-dependent impairment, the efficacy of V(IV) could not be assessed over 
the full 14-day treatment period. Moreover, V(IV) did not demonstrate significant 
antibacterial activity in any of the three tissues (joint fluid, bone marrow, and spongy 
bone) after the 4-day treatment. Of the different treatments [V(CDA10%) and V(CDA10%) + 
V(IV)], only treatment with CDA-vancomycin plus constant infusion of vancomycin 
[V(CDA10%) + V(IV)] showed a significant inhibitory effect in joint fluid, with P<0.05 after 14 
days of treatment.  
Treatment with 10% vancomycin-loaded CDA alone exhibited a greater activity than V(IV) 
alone (P<0.01), but combining these treatments significantly enhanced treatment efficacy (P 
<0.001). V(CDA10%) did not exhibit greater efficacy after 14 days compared with 4 days. In 
spongy bone and bone marrow, most samples were sterile after 14 days of treatment with 
CDA-vancomycin plus intravenous vancomycin [V(CDA10%) + V(IV)], but none after V(CDA10%). 
www.intechopen.com
 
Biomaterials Applications for Nanomedicine 
 
202 
Furthermore, the combined V(CDA10%) + V(IV) treatment seemed to be the most effective. 
These data indicate the addition of a local delivery system enhanced the antibacterial effects 
of these drugs in a tissue-specific manner. One possible mechanism for the enhanced 
efficacy of the combined treatment is that the release of vancomycin loaded onto CDA is 
limited to the site of infection, with cortical bone acting as a semi-permeable membrane and 
preventing the elimination of vancomycin through the bloodstream. 
 
 
ND: not done n: number of animals a P<0.05 vs day 3  b P<0.05 vs V(CDA10%) and V(IV)  
*under the lower limit of detection 
Table 5. Bacterial counts in joint fluid (JF), bone marrow (BM), and spongy bone (Bo) at day 
3 (post-inoculation) and 4 and 14 days after the beginning of the treatment. 
5. Conclusion  
Biomaterials as local DDS could reduce or eliminate the toxic side effects and complications 
of systemic antibiotic treatments, enhancing patient safety. From this perspective, the 
reference antibiotic against MRSA, vancomycin, was selected, and optimized concentrations 
were loaded into a CaP matrix (CDA) by wet granulation. The in vitro antibacterial activity 
of eluents from the DDS showed that the nature of the antibiotics was not altered either as a 
result of CDA loading or after sustained release from the granules. After a 14-day in vitro 
release, the CDA matrix was still able to deliver antibiotics at a concentration 50 times 
greater than the MIC of the MRSA strain used, providing local effective bactericidal 
concentrations of antibiotic and not inducing the development of antibiotic resistance from a 
slow residual release at suboptimal antibiotic concentrations. While more traditional 
antibiotic carrier systems are available, CDA has both desirable antibiotic release kinetics 
and a high osteogenic-promoting activity, including degradation of the apatite, obviating 
the need for a second surgery to remove the implanted material.  
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